RespireRx Pharmaceuticals Inc.

Equities

RSPI

US7612273059

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:48:57 2024-05-28 EDT			5-day change	1st Jan Change
0.0008 ^USD	+14.29%		0.00%	-11.11%

04-10	RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	CI
03-20	RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	CI

Respirerx Pharmaceuticals Inc. Announces Resignation of James Sapirstein as Board of Directors and Other Committees

December 30, 2019 at 09:18 am

RespireRx Pharmaceuticals Inc. announced resignation of James Sapirstein from the Board of Directors of the company and all committees of the Board on which he serves, effective as of December 20, 2019.

Latest news about RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	04-09	CI
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	03-20	CI
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine	02-13	CI
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors	01-22	CI
Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	01-04	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
RespireRx Pharmaceuticals Inc. announced that it has received $0.25 million in funding from ARNOLD LIPPA FAMILY TRUST OF 2007	23-05-21	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
RespireRx Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	23-04-16	CI
RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders	23-04-05	CI
RespireRx Pharmaceuticals Inc. announced that it has received $0.025 million in funding	23-04-04	CI
RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects Without Sedation	23-04-03	CI
Respirerx Pharmaceuticals Inc. Announces Appointment of Joseph Siegelbaum as Independent Member of the Board of Directors	23-03-28	CI
ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd	23-03-01	CI
RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform	23-01-12	CI
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development	22-12-05	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22	CI
RespireRx Pharmaceuticals Inc. Announces Board Changes	22-08-03	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
Respirerx Pharmaceuticals Inc. Enters into First Amendment to Certain Promissory Note	22-05-16	CI
RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of Gabakine Neuromodulators for the Treatment of Tinnitus	22-05-16	CI
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI

Chart RespireRx Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

RespireRx Pharmaceuticals Inc. develops treatments to combat disorders caused by disruption of neuronal signaling. The Company is developing treatment options that address conditions, such as obstructive sleep apnea (OSA), attention deficit hyperactivity disorder, epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect millions of people, as well as certain orphan disorders such as GRIA. It also considers developing treatment options for other conditions based on results of preclinical and clinical studies to date. The Company has two business units. ResolutionRx unit holds its pharmaceutical cannabinoids platform, and is developing compounds that target the bodyâs endocannabinoid system, and in particular, the re-purposing of dronabinol for the treatment of OSA. EndeavourRx is its neuromodulators platform, which is made up of two programs: AMPAkines program and GABAkines program.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RESPIRERX PHARMACEUTICALS INC.	-11.11%	644K
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-1.69%	21.83B
GENMAB A/S	-10.23%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs